Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Finished Goods (2017 - 2023)

Perspective Therapeutics' Finished Goods history spans 11 years, with the latest figure at $20000.0 for Q3 2023.

  • On a quarterly basis, Finished Goods fell 25.93% to $20000.0 in Q3 2023 year-over-year; TTM through Sep 2023 was $20000.0, a 25.93% decrease, with the full-year FY2022 number at $21000.0, changed N/A from a year prior.
  • Finished Goods hit $20000.0 in Q3 2023 for Perspective Therapeutics, up from $18000.0 in the prior quarter.
  • Over the last five years, Finished Goods for CATX hit a ceiling of $49000.0 in Q2 2021 and a floor of $7000.0 in Q4 2019.
  • Historically, Finished Goods has averaged $22368.4 across 5 years, with a median of $21000.0 in 2022.
  • Biggest five-year swings in Finished Goods: crashed 72.97% in 2019 and later soared 314.29% in 2021.
  • Tracing CATX's Finished Goods over 5 years: stood at $7000.0 in 2019, then changed by 0.0% to $7000.0 in 2020, then soared by 314.29% to $29000.0 in 2021, then dropped by 27.59% to $21000.0 in 2022, then decreased by 4.76% to $20000.0 in 2023.
  • Business Quant data shows Finished Goods for CATX at $20000.0 in Q3 2023, $18000.0 in Q2 2023, and $15000.0 in Q1 2023.